Kwality Pharmaceuticals Limited (NSE:KPL)

Market Cap	22.15B +196.8%
Revenue (ttm)	5.03B +36.7%
Net Income	673.46M +69.0%
EPS	64.90 +69.0%
Shares Out	n/a
PE Ratio	32.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,497
Average Volume	51,447
Open	2,127.00
Previous Close	2,087.00
Day's Range	2,065.00 - 2,140.00
52-Week Range	1,561.00 - 2,210.00
Beta	n/a
RSI	77.29
Earnings Date	May 19, 2026

About Kwality Pharmaceuticals

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, an...

• Industry: Pharmaceutical Preparations
• Founded: 1983
• Employees: 997
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KPL

Financial Performance

In fiscal year 2026, Kwality Pharmaceuticals's revenue was 5.06 billion, an increase of 36.67% compared to the previous year's 3.70 billion. Earnings were 673.46 million, an increase of 69.02%.